BrightFocus Foundation’s newly released research portfolios highlight the more than 250 active grants across our Alzheimer’s Disease Research, National Glaucoma Research, and Macular Degeneration Research programs in pursuit of discovering cures for diseases of mind and sight.
A new BrightFocus-funded clinical trial is one of the first to study the benefits of exercise in protecting brain health specifically among older African Americans.
The U.S. Food and Drug Administration in November granted Breakthrough Therapy designation for a new treatment that could slow the progression of geographic atrophy, an advanced and severe form of dry age-related macular degeneration that can lead to permanent vision loss.
The U.S. Food and Drug Administration today approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease based on its ability to clear toxic amyloid from the brain. It is the only drug in the class of amyloid immunotherapies shown to slow cognitive decline and will be available during or before the week of Jan. 23, 2023.
January is National Glaucoma Awareness Month, and BrightFocus Foundation is offering a variety of free educational resources to help individuals with glaucoma and their loved ones navigate the disease.
Nearly 20 million adults in the U.S. have some form of age-related macular degeneration, almost double the previous estimate of 11 million people, according to a new report. Learn why.
Global brain and vision research nonprofit BrightFocus Foundation has appointed digital health executive, entrepreneur, and speaker Paul A. Campbell as a new member of its board of directors.
A new blood test that could facilitate a more accurate diagnosis of Alzheimer’s during the initial phases of the disease is on the way—rooted in critical early support from Alzheimer’s Disease Research, a program of BrightFocus Foundation. Catching the disease as soon as possible offers affected individuals the greatest gift of all—more time to spend with loved ones and explore disease management and treatment options.
A team of BrightFocus-funded scientists has proposed a new explanation and possible new target for treatment in glaucoma that’s unrelated to the common culprit of eye pressure.
David Liao, MD, offers insights into managing and understanding AMD and what forthcoming FDA approval could mean for treatment.